Pharming Group reports third quarter 2023 financial results. Third quarter 2023 revenues increased 23% to US $66.7 million, compared to the third quarter 2022, driven by RUCONEST ® revenue and ...

Pharming has sawed off its gene therapy collaboration with Orchard, a decision that will see the end of a preclinical hereditary angioedema drug.

Pharming Group specializes in rare and genetic diseases. Click here to explore their revenue growth and foray into organ transplantation, along with challenges faced.

Pharming is paying $66.1 million to acquire the Swedish biotech Abliva and its phase 2-stage med for a type of mitochondrial disease.

Pharming Group drug Joenja was awarded FDA approval for treating a primary immunodeficiency called activated phosphoinositide 3-kinase delta syndrome, or APDS. It’s the first treatment for the ...

Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is involved in the ...

A high-level overview of Pharming Group N.V. (PHAR) stock. View (PHAR) real-time stock price, chart, news, analysis, analyst reviews and more.

Fabrice Chouraqui, Chief Executive Officer of Pharming, said: “This positive recommendation for Joenja® from NICE is a significant milestone for patients living with APDS in England and Wales.

A Columbia study addresses a key challenge in the diagnosis of rare genetic disorders.

The U.S. Food and Drug Administration (FDA) on Friday approved Pharming Group's drug to treat a rare genetic disorder that leads to a weakened immune system, the Dutch company said.

Pharming Group (PHGUF) reports a 42% revenue increase, driven by Ruconest and Joenja sales, while navigating acquisition costs and potential tariff challenges.